Azenta Life Sciences (Nasdaq: AZTA) provides end-to-end infrastructure for biological sample management and genomic data, serving pharmaceutical companies, biotech firms, and research institutions worldwide. Its platform combines physical storage, laboratory automation, cold-chain logistics, and informatics with genomic sequencing services, allowing customers to manage samples from collection through analysis within a single integrated system.
On the engineering side, Azenta's work spans cryogenic hardware, informatics, and data management. Core technical domains include:
- Automated cryogenic storage systems operating at -190°C
- Ultra-low temperature freezers and automated biorepositories
- Cold-chain logistics for temperature-controlled sample transport
- Informatics platforms maintaining chain-of-custody tracking across global facilities
- Genomic sequencing services through its GENEWIZ business
- Multiomics data support and bioinformatics
The scale of operations is substantial: Azenta manages over one billion biological samples worldwide and counts all 20 of the top 20 pharmaceutical and biotech companies among its customers. Its systems are designed to eliminate the manual handling, sample degradation, and data fragmentation that arise when biological materials are stored and tracked across disparate facilities.
Azenta's product engineering addresses the reliability and precision demands of drug discovery, clinical trials, and cell and gene therapy development - domains where sample integrity and data traceability directly affect research outcomes and regulatory compliance.
